Clinical Trials · NCT01686945

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Name: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Semaglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 107
Start date: Sep 2012
Locations: 1 site, Germany
Primary endpoint: Number of treatment emergent adverse events (TEAEs) recorded

View Semaglutide compound reference